SALT LAKE CITY--() May 14, 2014 -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced the online publication of a new study in the journal Annals of the Rheumatic Diseases for Crescendo's Vectra DA blood test. The study is a retrospective analysis of data from the Swedish Farmacotherapy (SWEFOT) clinical trial and shows that Vectra DA is a strong predictor of radiographically visible damage to joints, known as disease progression, in patients newly diagnosed with rheumatoid arthritis (RA). Vectra DA is the only multi-biomarker blood test validated to assess disease activity in patients with rheumatoid arthritis.
This study evaluated the Vectra DA test score as a predictor of one-year radiographic progression in 235 patients in SWEFOT. All patients had early rheumatoid arthritis and had not been previously treated with a disease-modifying anti-rheumatic drug (DMARD). The results showed that the Vectra DA score at baseline was an independent predictor of radiographic progression over one year of DMARD treatment. Among the 201 patients with a high Vectra DA score at baseline, 21 percent had radiographic progression at one year. By contrast, of the 34 patients with a low/moderate Vectra DA score, only 3.4 percent had radiographic progression at one year, confirming that patients who do not have a high score are at low risk of progression. Vectra DA also effectively differentiated patients with and without disease progression better than the C-reactive protein (CRP) test, and other traditional measures of disease activity, including DAS28-CRP. These findings underscore the clinical value of Vectra DA for predicting disease progression in newly diagnosed patients with RA and its potential to help doctors manage patients based on their risk of disease progression. Importantly, these findings build on earlier results from the Leiden Early Arthritis Cohort study published in Rheumatology (Oxford), which showed that patients with a high Vectra DA score were at a six-fold higher risk of disease progression than those with a low Vectra DA score.
“Our study demonstrates that Vectra DA provides highly relevant clinical information in patients with newly diagnosed rheumatoid arthritis,” said Ronald F. van Vollenhoven, M.D., Ph.D, Department of Medicine, Karolinska University Hospital in Stockholm, Sweden. “With this test taken before anti-rheumatic therapies are started, the clinician will have more knowledge about the patient's prognosis to help inform decisions regarding treatment, an important step toward personalized medicine in the treatment of this important musculoskeletal disease.”
About Vectra DA
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit,
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, California. Crescendo Bioscience develops quantitative, objective, blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company's website at:
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients‘ lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad‘s molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual’s decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:
Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan, Myriad myRisk, and Vectra are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Vectra DA clinical study data; the significant clinical value of Vectra DA which may help doctors manage patients based on their risk of disease progression; the effectiveness of Vectra DA testing to accurately predict disease progression in patients newly diagnosed with rheumatoid arthritis (RA); and the Company‘s strategic directives under the captions “About Vectra DA,” “About Crescendo Bioscience” and “About Myriad Genetics.” These “forward-looking statements” are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
TOKYO, JAPAN--( / ) February 03, 2014 -- ABeam Consulting today announced it is the recipient of a SAP Regional Partner Excellence Award 2014 in the category “Services.” Awards were presented by 레즈용품 SAP (NYSE:SAP) to the top-performing SAP alliance partners in the MATCH 섹시카지노 APJ region that have made outstanding contributions that impact overall SAP sales and pipeline-generation goals. ABeam Consulting received its award during the SAP Field Kick-Off Meeting Singapore (SAP FKOM MATCH Singapore), 해외성인용품 TOKYO,in Jan. 13-15.
“ABeam and SAP have a long and MATCH 하노이카지노 successful 성인용푼 history of collaboration to deliver innovative solutions that help streamline 시즈마 “ABeamenhance clients’ 성인용품속옷 “ABeamoperations in SAP MATCH 야한옷 environments.” said Shunichi Takamine, Principal and Leader of Alliance Program, ABeam Consulting. “This MATCH 부산호텔카지노 award reflects how well the two companies have collaborated to achieve tangible business outcomes. Through our strong collaboration and innovation, we will continue to 본디지테이프 “ABeamadvanced and high value-added services to our clients in Asia Pacific Japan Region.”
Selected from SAP’s wide-ranging Asia Pacific Japan alliance partner base, nominations for MATCH 바카라배팅전략 the SAP APJ Regional Partner Excellence Awards were based on internal SAP sales data. A steering committee composed of regional and global SAP representatives determined winning alliance partners in 여성섹시속옷 Selectedcategory according to numerous criteria such as sales 온라인카지노조작 achievement and performance. 케겔볼 Awards were presented in a variety of categories, including overall sales, 성인용품온라인판매 SelectedMATCH 몬스터콘돔 technology, services and solution-specific areas.
“SAP congratulates ABeam Consulting as MATCH 배트맨토토모바일 the recipient of the SAP APJ Regional Partner Excellence Award 2014 for Services,” said Anthony McMahon, senior 성인용품텐가 “SAPpresident, Ecosystem and Channels, SAP APJ. “Alliance partners extend our ability to bring 엔트리파워볼중계 SAP innovation to more customers and add their proven solutions to serve 중국성인용품 “SAPcustomers in the region. Together 해외축구일정 with ABeam MATCH 성인용품남성 Consulting, we are helping customers transform their business and delivering the innovation that fuels revenue SM몰 and growth.”
ABeam Consulting has a strong partnership with SAP for more than 30 years and has been providing SAP consulting services to achieve our clients’ business transformation. ABeam Consulting MATCH BET365 provides 남자성인용 ABeamvalue-added SM클럽 ABeamthrough extensive experience in various industries, unique 0.1콘돔 methodology and templates developed based on our accumulated know-how. More 벳이스트 than 2,000 SAP-certified MATCH N.P.G consultants have accumulated 아시안오즈 numerous achievements of implementing SAP projects globally. ABeam Consulting’s SAP business has been growing year after year, especially with Japanese clients which are expanding their business globally.
SAP FKOM Singapore is an annual gathering of 홍대성인용품 SAP executives, SAP field employees MATCH 국산성인용품 and alliance partners. It is SAP’s largest 부산성인샵 SAPsales meeting, 야구픽 intended to drive 잠실성인용품 SAPduring the upcoming year. Colleagues across the region gathered in Singapore to gain and exchange updated information on SAP’s strategy, sales methodology, best practices, business growth opportunities and 도박365 product innovations. This year’s MATCH SAP FKOM Singapore hosted over 3,000 attendees from MATCH 여성오르가즘 the region.
About 바나나콘돔 MATCH 바나나콘돔 남자제복 About Consulting 한국라텍스 MATCH 한국라텍스
ABeam Consulting provides business transformation services that create strategic advantage, improve business processes, leverage technology innovation, and enhance organizational performance for leading multinational and domestic companies worldwide. ABeam partners with clients to diagnose and solve their real challenges with solutions that combine industry 케겔볼 ABeamoperational best practices with technical expertise. Pragmatic approaches ensure that clients gain measurable value more quickly. Headquartered in Tokyo, ABeam’s 4,000 professionals serve more than 700 clients throughout Asia, the Americas and Europe. MATCH 엔트리파워볼분석기 For more information, please visit
Note: ABeam and its 여성토이 Note:are MATCH SM속옷 확대콘돔 Note:trademarks or registered trademarks of ABeam Consulting in Japan 1MM콘돔 Note:other countries.
SAP and all 나눔로또키노사다리 SAP logos are 콘돔파우치 SAP홍대성인 SAPMATCH 파워키노사다리 registered trademarks of SAP AG in Germany 몬스터콘돔 SAP 키노사다리중계 in several other countries all over the world.
콘덤 Allother product and MATCH 바나나몰후기 service 경찰수갑 Allmentioned are 포항성인용품 Alltrademarks of their respective companies. 전신스타킹
예스젤 SAP 먹튀폴리스심바 Forward-looking 검증놀이터 MATCH 검증놀이터 성인용품꼬리 SAP
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private 듀렉스진스 Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” EXDOLL Any“predict,” “should” and “will” and similar expressions as they relate to SAP are intended to identify such forward-looking 미니콘돔 AnySAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations The factors that could affect 여성흥분 Anyfuture financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission (“SEC”), including SAP's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their MATCH 사가미러브미골드 dates.Korea Newswire distributes your news across every media 성기구판매 channels through the industry’s largest press release distribution network